Prelude Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Prelude Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.71M	Buy	+54,292	New	+$1.6M	0.12%	203
2025 Q2	–	Sell	-22,800	Closed	-$553K	–	1054
2025 Q1	$553K	Buy	+22,800	New	+$513K	0.04%	474
2024 Q4	–	Sell	-12,325	Closed	-$245K	–	1265
2024 Q3	$245K	Sell	12,325 -10,525	-46%	-$195K	0.01%	972
2024 Q2	$354K	Sell	22,850 -3,049	-12%	-$47.5K	0.02%	715
2024 Q1	$413K	Sell	25,899 -26,408	-50%	-$398K	0.02%	717
2023 Q4	$879K	Buy	52,307 +38,303	+274%	+$524K	0.06%	324
2023 Q3	$164K	Buy	+14,004	New	+$187K	0.01%	946
2019 Q3	–	Sell	-23,270	Closed	-$89K	–	1754
2019 Q2	$89K	Buy	+23,270	New	+$101K	﹤0.01%	977
2017 Q4	–	Sell	-270	Closed	-$1K	–	1407
2017 Q3	$1K	Sell	270 -540	-67%	-$1.48K	﹤0.01%	1567
2017 Q2	$2K	Buy	+810	New	+$1.69K	﹤0.01%	1522

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Prelude Capital Management's CPRX Position: Q2 2026 in Review

Prelude Capital Management opened a new position in Catalyst Pharmaceutical (CPRX) in Q2 2026: 54,292 shares worth $1.71M. The stake represents 0.12% of the portfolio and ranks #203 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in CPRX as recently as Q1 2025.

Prelude Capital Management first reported a position in CPRX in Q2 2017 and has held it in 10 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

Prelude Capital Management held 54,292 shares of Catalyst Pharmaceutical worth $1.71M as of Q2 2026.
Catalyst Pharmaceutical was a new Prelude Capital Management position in Q2 2026.
Catalyst Pharmaceutical made up 0.12% of Prelude Capital Management's portfolio in Q2 2026, its #203 holding.
Prelude Capital Management first reported a position in Catalyst Pharmaceutical in Q2 2017 and has held it in 10 quarters since.
396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.